AstraZeneca’s acquisition of Alexion cleared in Europe

50
5
Favorite

AstraZeneca’s acquisition of Alexion cleared in Europe

seekingalpha2021-07-06

AstraZeneca(NASDAQ:AZN)hasreceivedthe clearance from the European Commission for its proposed acquisition of rare disease specialist Alexion Pharmaceuticals(NASDAQ:ALXN). Thedeal valued at $39Bwas ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（5）

siripab
·2021-07-06
Interesting
Reply
Like
Report
Kelowee
·2021-07-06
Like comment ??
Reply
1
Report
Fold Replies
- KS_Lee:
  Done.
  2021-07-06
  Reply
  Report
zhiwei1710
·2021-07-06
Pls like
Reply
5
Report
Fold Replies
- raredom:
  Donr
  2021-07-06
  Reply
  Report
- FrankPang:
  Ok
  2021-07-06
  Reply
  Report
limcainen
·2021-07-06
Like and comment
Reply
7
Report
Fold Replies
- SGX500:
  Nice
  2021-07-06
  Reply
  Report
- zwywz:
  comment
  2021-07-06
  Reply
  Report
- Crappybara:
  Good
  2021-07-06
  Reply
  Report
Qwer1234
·2021-07-06
ok
Reply
7
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1195559199?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-07-06 18:53","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1195559199","market":"us","top_or_hot":-1,"title":"AstraZeneca’s acquisition of Alexion cleared in Europe","media":"seekingalpha","content":"<div>\n<p>AstraZeneca(NASDAQ:AZN)hasreceivedthe clearance from the European Commission for its proposed acquisition of rare disease specialist Alexion Pharmaceuticals(NASDAQ:ALXN).\nThedeal valued at $39Bwas ...</p>\n\n<a href=\"https://seekingalpha.com/news/3712795-astrazenecas-acquisition-of-alexion-cleared-in-europe\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca’s acquisition of Alexion cleared in Europe</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca’s acquisition of Alexion cleared in Europe\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3712795-astrazenecas-acquisition-of-alexion-cleared-in-europe><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AstraZeneca(NASDAQ:AZN)hasreceivedthe clearance from the European Commission for its proposed acquisition of rare disease specialist Alexion Pharmaceuticals(NASDAQ:ALXN).\nThedeal valued at $39Bwas ...</p>\n\n<a href=\"https://seekingalpha.com/news/3712795-astrazenecas-acquisition-of-alexion-cleared-in-europe\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AZN","symbol_name":"阿斯利康","start_time":0,"source_url":"https://seekingalpha.com/news/3712795-astrazenecas-acquisition-of-alexion-cleared-in-europe","article_id":"1195559199","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195559199","pubTimestamp":1625568813,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"AstraZeneca(NASDAQ:AZN)hasreceivedthe clearance from the European Commission for its proposed acquis","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"AZN":"阿斯利康"},"translate_title":"阿斯利康收购Alexion在欧洲获得批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":0.9},"content_text":"AstraZeneca(NASDAQ:AZN)hasreceivedthe clearance from the European Commission for its proposed acquisition of rare disease specialist Alexion Pharmaceuticals(NASDAQ:ALXN).\nThedeal valued at $39Bwas previously cleared in the U.S., Japan, and several other countries. The competition clearance from the U.K. is pending, the company said in a statement.\nOn May 11, the shareholders of both companies have approved the acquisition following which a group focused on rare diseases will be created. The unit named ‘Alexion, AstraZeneca Rare Disease’ will be based on Boston, Massachusetts.\n“We are now another step closer to closing the acquisition and combining the two companies to create a leader in immunology and precision medicines. We continue to progress towards the completion of the acquisition during this quarter,\" commented Marc Dunoyer AstraZeneca CFO.\nAstraZeneca is not concerned about potential competition concerns in the U.K. that could derail its acquisition of Alexion,Dealreporternoted in May citing sourcesfamiliar with the matter.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":157165313,"gmtCreate":1625573582932,"gmtModify":1703744021246,"author":{"id":"3575890537963848","authorId":"3575890537963848","authorIdStr":"3575890537963848","name":"siripab","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575890537963848"},"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157165313","repostId":1195559199,"repostType":4,"repost":{"id":"1195559199","pubTimestamp":1625568813,"share":"https://ttm.financial/m/news/1195559199?lang=&edition=fundamental","pubTime":"2021-07-06 18:53","market":"us","language":"en","title":"AstraZeneca’s acquisition of Alexion cleared in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=1195559199","media":"seekingalpha","summary":"AstraZeneca(NASDAQ:AZN)hasreceivedthe clearance from the European Commission for its proposed acquis","content":"<ul>\n <li>AstraZeneca(NASDAQ:AZN)hasreceivedthe clearance from the European Commission for its proposed acquisition of rare disease specialist Alexion Pharmaceuticals(NASDAQ:ALXN).</li>\n <li>Thedeal valued at $39Bwas previously cleared in the U.S., Japan, and several other countries. The competition clearance from the U.K. is pending, the company said in a statement.</li>\n <li>On May 11, the shareholders of both companies have approved the acquisition following which a group focused on rare diseases will be created. The unit named ‘Alexion, AstraZeneca Rare Disease’ will be based on Boston, Massachusetts.</li>\n <li>“We are now another step closer to closing the acquisition and combining the two companies to create a leader in immunology and precision medicines. We continue to progress towards the completion of the acquisition during this quarter,\" commented Marc Dunoyer AstraZeneca CFO.</li>\n <li>AstraZeneca is not concerned about potential competition concerns in the U.K. that could derail its acquisition of Alexion,<i>Dealreporter</i>noted in May citing sourcesfamiliar with the matter.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca’s acquisition of Alexion cleared in Europe</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca’s acquisition of Alexion cleared in Europe\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3712795-astrazenecas-acquisition-of-alexion-cleared-in-europe><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AstraZeneca(NASDAQ:AZN)hasreceivedthe clearance from the European Commission for its proposed acquisition of rare disease specialist Alexion Pharmaceuticals(NASDAQ:ALXN).\nThedeal valued at $39Bwas ...</p>\n\n<a href=\"https://seekingalpha.com/news/3712795-astrazenecas-acquisition-of-alexion-cleared-in-europe\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"source_url":"https://seekingalpha.com/news/3712795-astrazenecas-acquisition-of-alexion-cleared-in-europe","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1195559199","content_text":"AstraZeneca(NASDAQ:AZN)hasreceivedthe clearance from the European Commission for its proposed acquisition of rare disease specialist Alexion Pharmaceuticals(NASDAQ:ALXN).\nThedeal valued at $39Bwas previously cleared in the U.S., Japan, and several other countries. The competition clearance from the U.K. is pending, the company said in a statement.\nOn May 11, the shareholders of both companies have approved the acquisition following which a group focused on rare diseases will be created. The unit named ‘Alexion, AstraZeneca Rare Disease’ will be based on Boston, Massachusetts.\n“We are now another step closer to closing the acquisition and combining the two companies to create a leader in immunology and precision medicines. We continue to progress towards the completion of the acquisition during this quarter,\" commented Marc Dunoyer AstraZeneca CFO.\nAstraZeneca is not concerned about potential competition concerns in the U.K. that could derail its acquisition of Alexion,Dealreporternoted in May citing sourcesfamiliar with the matter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":157198834,"gmtCreate":1625570522328,"gmtModify":1703743961511,"author":{"id":"3579871664787622","authorId":"3579871664787622","authorIdStr":"3579871664787622","name":"Kelowee","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579871664787622"},"htmlText":"Like comment ??","listText":"Like comment ??","text":"Like comment ??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/157198834","repostId":1195559199,"repostType":4,"repost":{"id":"1195559199","pubTimestamp":1625568813,"share":"https://ttm.financial/m/news/1195559199?lang=&edition=fundamental","pubTime":"2021-07-06 18:53","market":"us","language":"en","title":"AstraZeneca’s acquisition of Alexion cleared in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=1195559199","media":"seekingalpha","summary":"AstraZeneca(NASDAQ:AZN)hasreceivedthe clearance from the European Commission for its proposed acquis","content":"<ul>\n <li>AstraZeneca(NASDAQ:AZN)hasreceivedthe clearance from the European Commission for its proposed acquisition of rare disease specialist Alexion Pharmaceuticals(NASDAQ:ALXN).</li>\n <li>Thedeal valued at $39Bwas previously cleared in the U.S., Japan, and several other countries. The competition clearance from the U.K. is pending, the company said in a statement.</li>\n <li>On May 11, the shareholders of both companies have approved the acquisition following which a group focused on rare diseases will be created. The unit named ‘Alexion, AstraZeneca Rare Disease’ will be based on Boston, Massachusetts.</li>\n <li>“We are now another step closer to closing the acquisition and combining the two companies to create a leader in immunology and precision medicines. We continue to progress towards the completion of the acquisition during this quarter,\" commented Marc Dunoyer AstraZeneca CFO.</li>\n <li>AstraZeneca is not concerned about potential competition concerns in the U.K. that could derail its acquisition of Alexion,<i>Dealreporter</i>noted in May citing sourcesfamiliar with the matter.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca’s acquisition of Alexion cleared in Europe</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca’s acquisition of Alexion cleared in Europe\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3712795-astrazenecas-acquisition-of-alexion-cleared-in-europe><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AstraZeneca(NASDAQ:AZN)hasreceivedthe clearance from the European Commission for its proposed acquisition of rare disease specialist Alexion Pharmaceuticals(NASDAQ:ALXN).\nThedeal valued at $39Bwas ...</p>\n\n<a href=\"https://seekingalpha.com/news/3712795-astrazenecas-acquisition-of-alexion-cleared-in-europe\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"source_url":"https://seekingalpha.com/news/3712795-astrazenecas-acquisition-of-alexion-cleared-in-europe","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1195559199","content_text":"AstraZeneca(NASDAQ:AZN)hasreceivedthe clearance from the European Commission for its proposed acquisition of rare disease specialist Alexion Pharmaceuticals(NASDAQ:ALXN).\nThedeal valued at $39Bwas previously cleared in the U.S., Japan, and several other countries. The competition clearance from the U.K. is pending, the company said in a statement.\nOn May 11, the shareholders of both companies have approved the acquisition following which a group focused on rare diseases will be created. The unit named ‘Alexion, AstraZeneca Rare Disease’ will be based on Boston, Massachusetts.\n“We are now another step closer to closing the acquisition and combining the two companies to create a leader in immunology and precision medicines. We continue to progress towards the completion of the acquisition during this quarter,\" commented Marc Dunoyer AstraZeneca CFO.\nAstraZeneca is not concerned about potential competition concerns in the U.K. that could derail its acquisition of Alexion,Dealreporternoted in May citing sourcesfamiliar with the matter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5137875,"gmtCreate":1625573883481,"gmtModify":1663230596352,"authorId":3579578865458065,"author":{"id":3579578865458065,"authorId":3579578865458065,"name":"KS_Lee","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":157198834,"type":1,"supId":0,"prevId":0,"content":"Done.","text":"Done.","html":"Done."}],"langContent":"EN"},{"id":157372539,"gmtCreate":1625569522721,"gmtModify":1703743939856,"author":{"id":"4087821155706100","authorId":"4087821155706100","authorIdStr":"4087821155706100","name":"zhiwei1710","avatar":"https://static.tigerbbs.com/7c1d781541fda6795c09daf476f12b3c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087821155706100"},"htmlText":"Pls like&nbsp;","listText":"Pls like&nbsp;","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/157372539","repostId":1195559199,"repostType":4,"repost":{"id":"1195559199","pubTimestamp":1625568813,"share":"https://ttm.financial/m/news/1195559199?lang=&edition=fundamental","pubTime":"2021-07-06 18:53","market":"us","language":"en","title":"AstraZeneca’s acquisition of Alexion cleared in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=1195559199","media":"seekingalpha","summary":"AstraZeneca(NASDAQ:AZN)hasreceivedthe clearance from the European Commission for its proposed acquis","content":"<ul>\n <li>AstraZeneca(NASDAQ:AZN)hasreceivedthe clearance from the European Commission for its proposed acquisition of rare disease specialist Alexion Pharmaceuticals(NASDAQ:ALXN).</li>\n <li>Thedeal valued at $39Bwas previously cleared in the U.S., Japan, and several other countries. The competition clearance from the U.K. is pending, the company said in a statement.</li>\n <li>On May 11, the shareholders of both companies have approved the acquisition following which a group focused on rare diseases will be created. The unit named ‘Alexion, AstraZeneca Rare Disease’ will be based on Boston, Massachusetts.</li>\n <li>“We are now another step closer to closing the acquisition and combining the two companies to create a leader in immunology and precision medicines. We continue to progress towards the completion of the acquisition during this quarter,\" commented Marc Dunoyer AstraZeneca CFO.</li>\n <li>AstraZeneca is not concerned about potential competition concerns in the U.K. that could derail its acquisition of Alexion,<i>Dealreporter</i>noted in May citing sourcesfamiliar with the matter.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca’s acquisition of Alexion cleared in Europe</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca’s acquisition of Alexion cleared in Europe\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3712795-astrazenecas-acquisition-of-alexion-cleared-in-europe><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AstraZeneca(NASDAQ:AZN)hasreceivedthe clearance from the European Commission for its proposed acquisition of rare disease specialist Alexion Pharmaceuticals(NASDAQ:ALXN).\nThedeal valued at $39Bwas ...</p>\n\n<a href=\"https://seekingalpha.com/news/3712795-astrazenecas-acquisition-of-alexion-cleared-in-europe\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"source_url":"https://seekingalpha.com/news/3712795-astrazenecas-acquisition-of-alexion-cleared-in-europe","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1195559199","content_text":"AstraZeneca(NASDAQ:AZN)hasreceivedthe clearance from the European Commission for its proposed acquisition of rare disease specialist Alexion Pharmaceuticals(NASDAQ:ALXN).\nThedeal valued at $39Bwas previously cleared in the U.S., Japan, and several other countries. The competition clearance from the U.K. is pending, the company said in a statement.\nOn May 11, the shareholders of both companies have approved the acquisition following which a group focused on rare diseases will be created. The unit named ‘Alexion, AstraZeneca Rare Disease’ will be based on Boston, Massachusetts.\n“We are now another step closer to closing the acquisition and combining the two companies to create a leader in immunology and precision medicines. We continue to progress towards the completion of the acquisition during this quarter,\" commented Marc Dunoyer AstraZeneca CFO.\nAstraZeneca is not concerned about potential competition concerns in the U.K. that could derail its acquisition of Alexion,Dealreporternoted in May citing sourcesfamiliar with the matter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5137314,"gmtCreate":1625570000435,"gmtModify":1663230596051,"authorId":3581768035538210,"author":{"id":3581768035538210,"authorId":3581768035538210,"name":"raredom","avatar":"https://static.tigerbbs.com/77737b5631b06cd6b34c3ca4f2e7ca21","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":157372539,"type":1,"supId":0,"prevId":0,"content":"Donr","text":"Donr","html":"Donr"},{"id":5137331,"gmtCreate":1625570129221,"gmtModify":1663230592834,"authorId":3562581813714490,"author":{"id":3562581813714490,"authorId":3562581813714490,"name":"FrankPang","avatar":"https://static.tigerbbs.com/aaa6febe46886634e58dd4a543aafe96","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":157372539,"type":1,"supId":5137314,"prevId":0,"content":"<u>Ok</u>","text":"<u>Ok</u>","html":"<u>Ok</u>"}],"langContent":"EN"},{"id":157346407,"gmtCreate":1625568891909,"gmtModify":1703743922682,"author":{"id":"3581732292369755","authorId":"3581732292369755","authorIdStr":"3581732292369755","name":"limcainen","avatar":"https://static.tigerbbs.com/348839af52a533d0af68ce7adb2e8f22","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581732292369755"},"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/157346407","repostId":1195559199,"repostType":4,"repost":{"id":"1195559199","pubTimestamp":1625568813,"share":"https://ttm.financial/m/news/1195559199?lang=&edition=fundamental","pubTime":"2021-07-06 18:53","market":"us","language":"en","title":"AstraZeneca’s acquisition of Alexion cleared in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=1195559199","media":"seekingalpha","summary":"AstraZeneca(NASDAQ:AZN)hasreceivedthe clearance from the European Commission for its proposed acquis","content":"<ul>\n <li>AstraZeneca(NASDAQ:AZN)hasreceivedthe clearance from the European Commission for its proposed acquisition of rare disease specialist Alexion Pharmaceuticals(NASDAQ:ALXN).</li>\n <li>Thedeal valued at $39Bwas previously cleared in the U.S., Japan, and several other countries. The competition clearance from the U.K. is pending, the company said in a statement.</li>\n <li>On May 11, the shareholders of both companies have approved the acquisition following which a group focused on rare diseases will be created. The unit named ‘Alexion, AstraZeneca Rare Disease’ will be based on Boston, Massachusetts.</li>\n <li>“We are now another step closer to closing the acquisition and combining the two companies to create a leader in immunology and precision medicines. We continue to progress towards the completion of the acquisition during this quarter,\" commented Marc Dunoyer AstraZeneca CFO.</li>\n <li>AstraZeneca is not concerned about potential competition concerns in the U.K. that could derail its acquisition of Alexion,<i>Dealreporter</i>noted in May citing sourcesfamiliar with the matter.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca’s acquisition of Alexion cleared in Europe</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca’s acquisition of Alexion cleared in Europe\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3712795-astrazenecas-acquisition-of-alexion-cleared-in-europe><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AstraZeneca(NASDAQ:AZN)hasreceivedthe clearance from the European Commission for its proposed acquisition of rare disease specialist Alexion Pharmaceuticals(NASDAQ:ALXN).\nThedeal valued at $39Bwas ...</p>\n\n<a href=\"https://seekingalpha.com/news/3712795-astrazenecas-acquisition-of-alexion-cleared-in-europe\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"source_url":"https://seekingalpha.com/news/3712795-astrazenecas-acquisition-of-alexion-cleared-in-europe","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1195559199","content_text":"AstraZeneca(NASDAQ:AZN)hasreceivedthe clearance from the European Commission for its proposed acquisition of rare disease specialist Alexion Pharmaceuticals(NASDAQ:ALXN).\nThedeal valued at $39Bwas previously cleared in the U.S., Japan, and several other countries. The competition clearance from the U.K. is pending, the company said in a statement.\nOn May 11, the shareholders of both companies have approved the acquisition following which a group focused on rare diseases will be created. The unit named ‘Alexion, AstraZeneca Rare Disease’ will be based on Boston, Massachusetts.\n“We are now another step closer to closing the acquisition and combining the two companies to create a leader in immunology and precision medicines. We continue to progress towards the completion of the acquisition during this quarter,\" commented Marc Dunoyer AstraZeneca CFO.\nAstraZeneca is not concerned about potential competition concerns in the U.K. that could derail its acquisition of Alexion,Dealreporternoted in May citing sourcesfamiliar with the matter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5137198,"gmtCreate":1625569224510,"gmtModify":1663230595534,"authorId":3574229303651505,"author":{"id":3574229303651505,"authorId":3574229303651505,"name":"SGX500","avatar":"https://static.tigerbbs.com/6b4498bea235dca251a166a6a1a967bc","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":157346407,"type":1,"supId":5137186,"prevId":0,"content":"Nice","text":"Nice","html":"Nice"},{"id":5137186,"gmtCreate":1625569146480,"gmtModify":1663230594477,"authorId":3586398844225483,"author":{"id":3586398844225483,"authorId":3586398844225483,"name":"zwywz","avatar":"https://static.tigerbbs.com/a36758de2af0c50b1178380113b21204","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":157346407,"type":1,"supId":0,"prevId":0,"content":"comment","text":"comment","html":"comment"},{"id":5137213,"gmtCreate":1625569300722,"gmtModify":1663230592534,"authorId":3581494316592228,"author":{"id":3581494316592228,"authorId":3581494316592228,"name":"Crappybara","avatar":"https://static.tigerbbs.com/0a085697d49b443650c5a80b0fa9a50f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":157346407,"type":1,"supId":0,"prevId":0,"content":"Good","text":"Good","html":"Good"}],"langContent":"EN"},{"id":157346390,"gmtCreate":1625568870410,"gmtModify":1703743921870,"author":{"id":"3572867061700089","authorId":"3572867061700089","authorIdStr":"3572867061700089","name":"Qwer1234","avatar":"https://static.tigerbbs.com/4f048323098795168028c3aee02d87a4","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3572867061700089"},"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157346390","repostId":1195559199,"repostType":4,"repost":{"id":"1195559199","pubTimestamp":1625568813,"share":"https://ttm.financial/m/news/1195559199?lang=&edition=fundamental","pubTime":"2021-07-06 18:53","market":"us","language":"en","title":"AstraZeneca’s acquisition of Alexion cleared in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=1195559199","media":"seekingalpha","summary":"AstraZeneca(NASDAQ:AZN)hasreceivedthe clearance from the European Commission for its proposed acquis","content":"<ul>\n <li>AstraZeneca(NASDAQ:AZN)hasreceivedthe clearance from the European Commission for its proposed acquisition of rare disease specialist Alexion Pharmaceuticals(NASDAQ:ALXN).</li>\n <li>Thedeal valued at $39Bwas previously cleared in the U.S., Japan, and several other countries. The competition clearance from the U.K. is pending, the company said in a statement.</li>\n <li>On May 11, the shareholders of both companies have approved the acquisition following which a group focused on rare diseases will be created. The unit named ‘Alexion, AstraZeneca Rare Disease’ will be based on Boston, Massachusetts.</li>\n <li>“We are now another step closer to closing the acquisition and combining the two companies to create a leader in immunology and precision medicines. We continue to progress towards the completion of the acquisition during this quarter,\" commented Marc Dunoyer AstraZeneca CFO.</li>\n <li>AstraZeneca is not concerned about potential competition concerns in the U.K. that could derail its acquisition of Alexion,<i>Dealreporter</i>noted in May citing sourcesfamiliar with the matter.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca’s acquisition of Alexion cleared in Europe</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca’s acquisition of Alexion cleared in Europe\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3712795-astrazenecas-acquisition-of-alexion-cleared-in-europe><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AstraZeneca(NASDAQ:AZN)hasreceivedthe clearance from the European Commission for its proposed acquisition of rare disease specialist Alexion Pharmaceuticals(NASDAQ:ALXN).\nThedeal valued at $39Bwas ...</p>\n\n<a href=\"https://seekingalpha.com/news/3712795-astrazenecas-acquisition-of-alexion-cleared-in-europe\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"source_url":"https://seekingalpha.com/news/3712795-astrazenecas-acquisition-of-alexion-cleared-in-europe","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1195559199","content_text":"AstraZeneca(NASDAQ:AZN)hasreceivedthe clearance from the European Commission for its proposed acquisition of rare disease specialist Alexion Pharmaceuticals(NASDAQ:ALXN).\nThedeal valued at $39Bwas previously cleared in the U.S., Japan, and several other countries. The competition clearance from the U.K. is pending, the company said in a statement.\nOn May 11, the shareholders of both companies have approved the acquisition following which a group focused on rare diseases will be created. The unit named ‘Alexion, AstraZeneca Rare Disease’ will be based on Boston, Massachusetts.\n“We are now another step closer to closing the acquisition and combining the two companies to create a leader in immunology and precision medicines. We continue to progress towards the completion of the acquisition during this quarter,\" commented Marc Dunoyer AstraZeneca CFO.\nAstraZeneca is not concerned about potential competition concerns in the U.K. that could derail its acquisition of Alexion,Dealreporternoted in May citing sourcesfamiliar with the matter.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":50,"commentSize":5,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}